Kososan, a Kampo medicine, prevents a social avoidance behavior and attenuates neuroinflammation in socially defeated mice
- 896 Downloads
Kososan, a Kampo (traditional Japanese herbal) medicine, has been used for the therapy of depressive mood in humans. However, evidence for the antidepressant efficacy of kososan and potential mechanisms are lacking. Recently, it has been recognized that stress triggers neuroinflammation and suppresses adult neurogenesis, leading to depression and anxiety. Here, we examined whether kososan extract affected social behavior in mice exposed to chronic social defeat stress (CSDS), an animal model of prolonged psychosocial stress, and neuroinflammation induced by CSDS.
In the CSDS paradigm, C57BL/6J mice were exposed to 10 min of social defeat stress from an aggressive CD-1 mouse for 10 consecutive days (days 1–10). Kososan extract (1.0 g/kg) was administered orally once daily for 12 days (days 1–12). On day 11, the social avoidance test was performed to examine depressive- and anxious-like behaviors. To characterize the impacts of kososan on neuroinflammation and adult neurogenesis, immunochemical analyses and ex vivo microglial stimulation assay with lipopolysaccharide (LPS) were performed on days 13–15.
Oral administration of kososan extract alleviated social avoidance, depression- and anxiety-like behaviors, caused by CSDS exposure. CSDS exposure resulted in neuroinflammation, as indicated by the increased accumulation of microglia, the resident immune cells of the brain, and their activation in the hippocampus, which was reversed to normal levels by treatment with kososan extract. Additionally, in ex vivo studies, CSDS exposure potentiated the microglial pro-inflammatory response to a subsequent LPS challenge, an effect that was also blunted by kososan extract treatment. Indeed, the modulatory effect of kososan extract on neuroinflammation appears to be due to a hippocampal increase in an anti-inflammatory phenotype of microglia while sparing an increased pro-inflammatory phenotype of microglia caused by CSDS. Moreover, reduced adult hippocampal neurogenesis in defeated mice was recovered by kososan extract treatment.
Our findings suggest that kososan extract prevents a social avoidant behavior in socially defeated mice that is partially mediated by the downregulation of hippocampal neuroinflammation, presumably by the relative increased anti-inflammatory microglia and regulation of adult hippocampal neurogenesis. Our present study also provides novel evidence for the beneficial effects of kososan on depression/anxiety and the possible underlying mechanisms.
KeywordsKampo Kososan Depression Anxiety Antidepressant-like effect Chronic social defeat stress Microglia Neuroinflammation Neurogenesis
Analysis of variance
Bovine serum albumin
Chronic social defeat stress
CX3C chemokine receptor 1
Dulbecco’s modified Eagle’s medium
Granular cell layer
Ionized calcium binding adaptor molecule 1
Nod-like receptor family, pyrin domain-containing 3
Peroxisome proliferator-activated receptor γ
Social avoidance test
Standard error of the mean
Long-lasting exposure to various stressors in humans often causes psychological disorders such as depression. Depression per se is not a life-threatening illness, although long-lasting depression could lead to various detrimental events including suicide , worsening of other diseases , and long-term absence from work , which can result in robust economic loss. Therefore, an effective treatment of depression is an urgent social and medical issue.
To date, a large body of research has attempted to elucidate the pathogenesis of depression by using animal models exposed to stressors. Among them, chronic social defeat stress (CSDS) is a psychosocial stress behavioral paradigm widely used with face, constructive, and predictive validity [4, 5, 6] and is currently used to study several psychiatric disorders and their pathologies. For example, CSDS is used to examine depression, anxiety, and the efficacy of therapeutic drugs to treat these conditions [7, 8, 9].
Recently, it has been well recognized that stress induces neuroinflammation via microglia, the resident immune cells of the brain [10, 11, 12, 13, 14], which potentially contributes to the onset of depression  and anxiety . Interestingly, the classical tricyclic antidepressant imipramine prevents neuroinflammation and behavioral deficits (depression- and anxiety-like behaviors) caused by CSDS [17, 18]. In addition, studies without stress exposure found that interferon-alpha (IFN-α) therapy elicited neuroinflammation as well as depression-like behaviors , both of which were prevented by minocycline, an inhibitor of microglial activation . Microglial activation is also well known to be categorized into the classical M1 and alternative M2 phenotypes [21, 22, 23]. M1 microglia produce pro-inflammatory cytokines (i.e., IL-1β, IL-6, TNF-α), inducible nitric oxide, and reactive oxygen species that lead to cell damage. M2 microglia serve as an anti-inflammatory phenotype that is involved in tissue repair and remodeling. Thus, M1 and M2 microglia are considered to act as inducers and suppressors of neuroinflammation, respectively. A more recent study has shown that pioglitazone, a highly selective agonist for peroxisome proliferator-activated receptor γ (PPARγ), exerts an antidepressant-like activity through PPARγ-mediated amelioration of M1/M2 microglial imbalance in chronic mild stress-induced depression-like model mice . Taken together, these findings suggest that microglia-mediated neuroinflammation could be a therapeutic target in treating depression and anxiety.
Kososan, a Kampo (traditional Japanese herbal) medicine, is composed of five herbs (Cyperi Rhizoma, Perillae Herba, Aurantii Nobilis Pericarpium, Glycyrrhizae Radix, and Zingiberis Rhizoma). Experientially, kososan is currently used to treat depressive mood disorders in addition to the initial stage of the common cold, allergic urticaria due to the ingestion of food, irritable bowel syndrome, chronic fatigue syndrome, insomnia, and autonomic imbalance. There is also modern clinical evidence showing that kososan attenuates depressive mood caused by IFN-α therapy for hepatitis C . Moreover, our previous animal studies have demonstrated that oral administration of kososan counteracted the depression-like behaviors of chronic mild stress-exposed or IFN-α-treated mice by normalizing the dysfunction of the hypothalamic-pituitary-adrenal axis, a region strongly associated with the pathogenesis of depression [26, 27], regulating the orexin/neuropeptide Y signaling system [28, 29], and by modulating metabotropic glutamate receptor 2 and 2′,3′-cyclic nucleotide 3′-phosphodiesterase 1 in the hypothalamus using a proteomic analysis . Furthermore, our recent study suggests that psychological stress-induced depression-like behaviors in mice were mitigated by treatment with kososan, but not the antidepressant milnacipran , a serotonin-noradrenaline reuptake inhibitor. Besides, many rodent studies have shown that some compounds (e.g., apigenin [32, 33], caffeic acid , perillaldehyde [35, 36], and rosmarinic acid  contained in Perillae Herba; hesperidin [38, 39] and nobiletin [40, 41] contained in Aurantii Nobilis Pericarpium) exert antidepressant-like effects. Although there is increasing evidence for kososan’s therapeutic benefits for depression-like behaviors in preclinical studies, little is known about the efficacy of kososan in the behavioral abnormalities caused by CSDS as an animal model of psychosocial stress. Therefore, in the present study, we examined whether kososan alters a social avoidant behavior and neuroinflammation in mice exposed to CSDS.
Male C57BL/6J (7 weeks of age) and CD-1 (retired breeders) mice were purchased from Japan SLC (Hamamatsu, Japan). All animals were allowed to acclimate for at least 1 week after arrival. The C57BL/6J mice were housed in cohorts of four to five, and the CD-1 mice were singly housed during acclimation. The animals were kept under a constant temperature (23 ± 2 °C), humidity (55 ± 10%), and a 12-h light cycle (lights on at 08:00), with food (CE-2, CLEA Japan, Inc., Tokyo, Japan) and water available ad libitum. All cages (22.5 × 33.8 × 14 cm, CLEA Japan, Inc.) were provided with wood bedding material (Japan Laboratory Animals, Inc., Tokyo, Japan). All animal experiments were approved by the Institutional Animal Care and Use Committee of Kitasato University and performed in accordance with the Guidelines for the Care and Use of Laboratory Animals of Kitasato University and the National Research Council Guide for the Care and Use of Laboratory Animals in Japan. Every effort was made to minimize the number of animals used and their suffering.
Preparation of kososan extract
The herbs in kososan were as follows: Cyperi Rhizoma (the rhizome of Cyperus rotundus L.), 4.0 g (Lot No. AE7951, Tsumura & Co., Tokyo, Japan); Perillae Herba (leaf of Perilla frutescens Britton var. acuta Kudo), 2.0 g (Lot No. B04401, Tsumura & Co.); Aurantii Nobilis Pericarpium (pericarp of Citrus unshiu Markovich), 3.0 g (Lot No. AD7971, Tsumura & Co.); Glycyrrhizae Radix (root of Glycyrrhiza uralensis Fisher), 2.0 g (Lot No. 8661621, Uchida Wakan-yaku Co. Ltd., Tokyo, Japan); and Zingiberis Rhizoma (rhizome of Zingiber officinale Roscoe), 0.5 g (Lot No. AK8761, Tsumura & Co.). Kososan was decocted with 600 ml of distilled water until the volume was reduced by half. The water extract was immediately filtered, centrifuged at 1000 × g for 10 min at 4 °C, and the supernatant lyophilized. Total yield of kososan extract was approximately 28% from the herbal mixture based on dry weight [26, 29, 31].
Bromodeoxyuridine (BrdU) injection
Drug treatment and measurement of body weight
Kososan extract was dissolved in distilled water. Kososan extract (1.0 g/kg) or distilled water was administered by oral gavage once daily for 12 consecutive days (Fig. 1a). The dose of kososan extract (1.0 g/kg) used in this study was chosen based on the findings that kososan extract exhibited an antidepressant-like effect in stress-induced mouse models of depression [26, 28, 29, 30, 31]. Body weight was measured prior to kososan extract administration each day.
CSDS was performed using similar methods described by Krishnan et al.  and Golden et al. . Briefly, each testing mouse (C57BL/6J) to be socially defeated was introduced into the home cage of an unfamiliar resident CD-1 aggressor mouse for 10 min daily for 10 consecutive days (days 1–10, Fig. 1a, b). The CD-1 mice were selected and designated as aggressors only if their attack latencies were shorter than 60 s on two to three consecutive screening tests. During the 10-min defeat period, most testing mice showed submissive postures (standing upright) against the aggressor mice. After 10 min of physical contact, the testing mouse and the resident aggressor mouse were each housed in one half of a cage separated by a clear perforated Plexiglas divider to allow sensory contact for the remainder of the 24-h period with free access to food and water. On each testing day, testing mice were defeated by novel aggressor mice to avoid habituation to individual aggressors. Undefeated control mice were handled every day, housed in pairs, separated by the perforated divider in cages identical to those used for socially defeated mice, rotated daily in a manner similar to the defeated mice, but were never exposed to aggressor mice. If mice did not show either submissive postures or flight behaviors during the last exposure of defeat stress, they were excluded as lack of defeat from subsequent experiments. CSDS was carried out between 13:00 h and 17:00 h. The morning after the last defeat session, both defeated and undefeated control mice were individually housed until the end of experiments.
Social avoidance test (SAT)
The SAT is composed of two 150-s phases [4, 43]. On day 11 (Fig. 1a, c), each mouse was introduced into an opaque gray open-field box (40 × 40 × 40 cm) with an empty wire-mesh Plexiglas enclosure (7 × 10 × 40 cm) located in the social interaction (SI) zone (13.5 × 24.0 cm) at one end of the box and allowed to explore freely for 150 s (the first phase). The mouse was then removed from the box and placed back into its home cage for roughly 1 min. In the second phase, the mouse was re-introduced into the box with an unfamiliar aggressor mouse and allowed to explore again for 150 s. Time spent in the SI zone as well as total distance moved during each phase was recorded by a video tracking system (EthoVision 3.0; Noldus, Wageningen, Netherlands). The SI ratio was calculated by dividing the time spent in the SI zone when the aggressor mouse was present by the time spent in the SI zone when the aggressor mouse was absent. The SAT was carried out between 12:00 h and 17:00 h.
On day 13 (Fig. 1a), under deep inhaled anesthesia with isoflurane (Pfizer, Tokyo, Japan), mice were transcardially perfused with cold phosphate-buffered saline (PBS), followed by a cold 4% paraformaldehyde solution (Wako Pure Chemical Industries, Osaka, Japan). The brains were collected and postfixed in a 4% paraformaldehyde solution at 4 °C overnight and then stored in 0.02% NaN3/PBS at 4 °C until brain sectioning.
Immunohistochemistry for ionized calcium binding adaptor molecule 1 (Iba1), CX3C chemokine receptor 1 (CX3CR1), and nod-like receptor family, pyrin domain-containing 3 (NLRP3)
Serial coronal sections (50 μm thick) were obtained throughout the hippocampus using a vibratome (Technical Products International, St. Louis, MO, USA). Staining was completed in 24-well plates for free-floating immunohistochemistry. After incubation with 3% H2O2/80% methanol for 40 min at room temperature (RT), free-floating sections were blocked for 1 h at RT with blocking buffer [1% bovine serum albumin (BSA; Wako Pure Chemical Industries) in PBS containing 0.3% Triton X-100 (PBS-T)]. Sections were subsequently incubated overnight at 4 °C with rabbit anti-Iba1 (1:1500, Wako Pure Chemical Industries), goat anti-CX3CR1 (1:50, Santa Cruz Biotechnology, Santa Cruz, CA, USA), or mouse anti-NLRP3 (1:1000, AdipoGen, San Diego, CA, USA) primary antibody in the blocking buffer. Sections were then rinsed in PBS-T, incubated for 1 h at RT with biotinylated goat anti-rabbit (1:500; Vector Laboratories, Burlingame, CA, USA), biotinylated donkey anti-goat (1:200, Santa Cruz Biotechnology), or biotinylated horse anti-mouse (1:200, Vector Laboratories) secondary antibody, followed by incubation for 1 h at RT with the ABC kit (Vector Laboratories). Iba1-, CX3CR1-, and NLRP3-positive cells were visualized with Vector DAB (Vector Laboratories). Sections were mounted on silane-coated slides, dried, counterstained with 0.05% toluidine blue (Sigma, St. Louis, MO, USA), dehydrated, and coverslipped. For quantitative assessment, counting of Iba1-positive cells was performed on every third section throughout the hippocampus of both brain hemispheres (bregma −1.5 to −2.6 mm) at ×400 magnification using a light microscope (Olympus BX-41, Olympus Corporation, Tokyo, Japan) in six sections per mouse. Likewise, CX3CR1- or NLRP3-positive cells were also counted on every seventh section throughout the hippocampus of a brain hemisphere, resulting in a total of three sections assessed per mouse.
Immunofluorescence staining of Iba1/CX3CR1 or NLRP3
Free-floating sections were incubated in 80% methanol for 20 min at RT. Sections were blocked for 1 h at RT and then incubated overnight at 4 °C with rabbit anti-Iba1 (1:1000) and goat anti-CX3CR1 (1:50) or mouse anti-NLRP3 (1:300) primary antibody in the blocking buffer. Sections were then incubated for 1 h at RT with appropriate Alexa Fluor 488- or 594-labeled secondary antibodies (1:1000, Molecular Probes, Eugene, OR, USA). After processing for 30 s with TrueBlack solution (Biotium, Hayward, CA, USA) to quench lipofuscin autofluorescence, sections were coverslipped with VECTASHIELD (Vector Laboratories). Images of double-stained cells in the dentate gyrus were taken at ×400 magnification with a fluorescence microscope (Olympus BX-41) using cellSens imaging software (Olympus Corporation).
Double immunohistochemistry for BrdU and doublecortin (DCX)
Microglia were isolated from adult testing mouse whole brain except the cerebellum as described previously [11, 46, 47] with some modifications. Briefly, following decapitation, the whole brain except the cerebellum was readily extracted and chopped finely with a fine sharp scissor in ice-cold serum-free Dulbecco’s modified Eagle’s medium (DMEM)/F12 (Sigma) containing papain (20 U/ml, Worthington Biochemical Corporation, Lakewood, NJ, USA), DNase I (2 mg/ml, Sigma), and 1% penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA). The brain pieces prepared were incubated in a water bath at 37 °C for 20 min. Enzymatic digestion with papain was terminated by adding ice-cold DMEM/F12 containing 20% horse serum (Invitrogen) and 1% penicillin/streptomycin. The brain pieces were further triturated by gently pipetting and passing the tissue through a 100-μm cell strainer (Greiner Bio-One, Tokyo, Japan) to remove cell debris and undigested tissue pieces. The filtered cell suspension was centrifuged at 1000 × g for 5 min at 4 °C, and the supernatant was decanted. The cell pellet was then re-suspended by slow pipetting with 30% isotonic Percoll (GE Healthcare, Tokyo, Japan) in Hank’s balanced salt solution without calcium and magnesium (Sigma) and centrifuged at 700 × g for 10 min at 4 °C. After centrifugation, the supernatant was aspirated, and the cell pellet was re-suspended by pipetting with a lysis buffer (150 mM NH4Cl, 0.24 mM NaHCO3, 0.068 mM EDTA in distilled water, pH 7.4) to remove red blood cells and then centrifuged at 1000 × g for 5 min at 4 °C. This process was repeated twice to eliminate the remaining dead cells, red blood cells, and Percoll. The cell pellet was re-suspended in DMEM/F12 containing 10% fetal bovine serum (Sigma) and 1% penicillin/streptomycin and filtered through 11-μm nylon mesh (Merck Millipore, Billerica, MA, USA). The harvested cells were counted using a hemocytometer and 0.1% trypan blue solution (Nacalai Tesque, Kyoto, Japan).
Ex vivo microglial stimulation assay with lipopolysaccharide (LPS)
Microglia were plated at a density of 5 × 104 cells/well in 96-well plates, kept in a 5% CO2 incubator at 37 °C for 30 min, and then stimulated with PBS or Escherichia coli LPS (serotype 0111:B4, 0.1 μg/ml, Sigma) for 18 h at 37 °C and 5% CO2. Supernatants were collected and stored at −80 °C until the interleukin-6 (IL-6) assay. The remaining cells were incubated with 10% alamarBlue (Thermo Fisher Scientific, Waltham, MA, USA) in DMEM/F12 for 2 h at 37 °C and 5% CO2, and cell viability was measured using fluoroscopy with the Infinite M200 microplate reader (Tecan Group Ltd., Männedorf, Switzerland) (excitation and emission wavelength at 544 and 590 nm, respectively).
IL-6 levels in supernatants collected from cell cultures were detected using a commercially available solid-phase sandwich ELISA (BD OptEIATM mouse IL-6 ELISA set, BD Biosciences, San Diego, CA, USA), in accordance with the manufacturer’s instructions. The sensitivity of the measurement was 3.8 pg/ml. The intra- and inter-assay coefficients of variations were 6.4–6.9 and 4–9.6%, respectively.
All data are presented as mean ± standard error of the mean (SEM) and analyzed using Prism (GraphPad Software, San Diego, CA, USA). For comparison between two groups, statistical analysis was performed by unpaired or paired t test. For comparison between three or more groups, statistical analysis was performed using a one-way analysis of variance (ANOVA) or two-way repeated measures ANOVA, followed by Bonferroni’s post hoc test. A chi-square test was used for comparison of the binary data from the SAT. In all cases, differences were considered statistically significant at p < 0.05.
Kososan extract reversed stress-induced social avoidance behaviors in mice
Kososan prevented stress-induced increases in hippocampal Iba1-positive cells and their aggregates in mice
Kososan extract mitigated the stress-enhanced IL-6 production from isolated microglia
Kososan extract regulated changes in an anti-inflammatory, but not pro-inflammatory, phenotype of microglia in socially defeated mice
Kososan extract alleviated the stress-elicited reduction in hippocampal neurogenesis
In the present study, avoidance behavior against aggressor mice was observed in the defeated mice. This was indicated by a significant reduction in the SI ratio relative to undefeated control mice and was significantly blocked by kososan extract treatment. Furthermore, these behavioral changes were unlikely to result from alterations in locomotor activity among the groups. Rodents innately have a character of overt sociability, frequently exhibited as sniffing and grooming one another. However, prolonged external aversive stimuli (e.g., defeat stress) can lead to reduced sociability and social avoidance, which is well considered to be a characteristic symptom of depression and anxiety [4, 43]. Therefore, recovery from defeat stress-triggered social avoidance behaviors by kososan extract treatment may represent antidepressant- and/or anxiolytic-like effects under conditions of psychosocial stress.
In defeated mice, greater body weight gain was found relative to undefeated control mice. This is consistent with numerous studies that found that CSDS induces an increase in body weight [52, 53, 54, 55, 56], which may result from stress-related hyperphagia or a metabolic aberration. However, the stress-induced increase in body weight was not affected by kososan extract treatment, suggesting that the observed behavioral recovery may be independent of mechanisms that influence body weight.
Accumulating evidence has shown that CSDS enhances microglia-mediated neuroinflammation in rodents [11, 12, 17, 57]. Consistent with these findings, defeated mice from the present study had an increase in Iba1-positive cells and their aggregates [58, 59] and an enhanced inflammatory response after a LPS challenge in isolated microglia. A microglial aggregation is considered to be a sign of microglial activation, thereby contributing to neuroinflammation and subsequent neuronal damages in the brain [59, 60]. It is therefore conceivable that kososan extract-induced reduction in the aggregates corroborates the blocking effect of microglial activation by kososan extract. An increase in CSDS-induced neuroinflammation was also observed as a LPS-stimulated elevation of IL-6 release from ex vivo microglia. These results may reflect stress-induced microglial priming (i.e., a reactive state in preparation for subsequent stimuli like stress or an immune challenge) that may enhance subsequent inflammatory responses [61, 62]. Surprisingly, these CSDS-induced alterations were mitigated by kososan extract treatment, raising a possibility that anti-social avoidant behavior by kososan extract is involved in the suppression of neuroinflammation. Future studies whether behavioral deficits and the corresponding neuroinflammation are blocked in mice administered kososan from after 10-day CSDS exposure will support the possibility. Given our results, the suppressive effect on the enhanced inflammatory response to LPS following treatment with kososan extract may be attributable to the inhibition of microglial priming. In addition, a more recent study has shown that psychological stress-triggered neuroinflammation is strongly linked to crosstalk of microglia with astrocytes, in which astrocyte-derived adenosine triphosphate by stress facilitates microglial activation via the purinergic type 2X7 receptor . Thus, further studies on the role of kososan extract in astrocyte function would be valuable for better understanding the effect of kososan extract on neuroinflammation.
In the present study, wounds were observed in some defeated mice. However, our data on behavioral outcomes and neuroinflammatory responses following CSDS were independent of the extent of wounds (data not shown), which was consistent with previously published studies showing that injuries in the CSDS paradigm did not affect subsequent behaviors and inflammatory responses [64, 65]. Therefore, in the present study, the extent of wounds after CSDS exposure is, at least, unlikely to be a confounding factor in the assessment of social behaviors and neuroinflammation.
M1 and M2 microglial imbalance is deeply linked to neuroinflammation in the CNS [23, 66, 67]. In our study, to further unravel the suppression of neuroinflammation by kososan extract, we examined the regulating effect of kososan extract on the hippocampal M1/M2 microglial balance. In the MOL, CSDS attenuated the anti-inflammatory profile of microglia, as indicated by decreased CX3CR1 (a marker of M2 microglia)-positive cells, an effect that was rescued by treatment with kososan extract. This result suggests that kososan extract mitigates neuroinflammation by increasing the population of anti-inflammatory microglia in the MOL. Conversely, in the SGZ of defeated mice, microglia were more likely to have a pro-inflammatory profile, as indicated by increased NLRP3 (a marker of M1 microglia)-positive and decreased CX3CR1-positive cell numbers, neither of which was affected by kososan extract treatment. These results suggest that the administration of kososan extract failed to attenuate neuroinflammation in the SGZ. Although further studies are necessary to verify the effects of kososan extract on other indicators of microglial phenotypes, our results imply that the effect of kososan extract on neuroinflammation may be due to an increase in the anti-inflammatory M2 phenotype of microglia rather than a decrease in the pro-inflammatory M1 phenotype. Likewise, distinct regional hippocampal differences in the distribution of NLRP3- and CX3CR1-positive cells may reflect a region-specific role of each microglial phenotype in the hippocampal circuitry, neurogenic niche, and behavioral outcomes.
Disruption of adult hippocampal neurogenesis, a well-known process involving the generation and functional integration of newborn cells into brain circuitry , plays an important role in the mechanisms by which stress facilitates depression [69, 70]. The hippocampus is a brain region particularly vulnerable to stress and inflammation, and therefore, we examined the impact of CSDS and kososan extract treatment on adult hippocampal neurogenesis. A defeat stress-induced reduction in the survival of newborn cells and their proliferation in the SGZ, as demonstrated by decreased total BrdU- and Ki67-positive cells, was not blunted by kososan extract treatment. However, kososan extract restored the CSDS-induced reduction in neuronal differentiation. These results indicate that kososan extract partially alleviates a stress-triggered disruption of adult hippocampal neurogenesis. A previous report has demonstrated that restraint stress-induced neuroinflammation (i.e., increased activated microglia and NLRP3 expression) was associated with impaired neurogenesis, which is required for depression-like behaviors in mice . CX3CR1 and its ligand fractalkine have also been reported to regulate adult hippocampal neurogenesis in rodents . For example, the disruption of fractalkine/CX3CR1 signaling in adult CX3CR1-deficient mice causes a disturbance in adult hippocampal neurogenesis. Taken together, these findings support our results that a CSDS-induced reduction in CX3CR1-positive cells along with an increase in NLRP3-positive cells in the SGZ may be reciprocally involved in the disruption of neurogenesis, indicated by a reduced number of BrdU/DCX-positive cells. Furthermore, our study found that kososan extract treatment prevented the CSDS-induced disruption of neurogenesis without reversing the reduction in CX3CR1-positive cells and the increase in NLRP3-positive cells caused by stress in the SGZ. In light of our results with previous findings, there appears to be a partial discrepancy in the relationship between cell differentiation, CX3CR1 expression, and NLRP3 expression in the SGZ of kososan extract-treated mice, in a region-specific manner. It is possible that kososan extract may exert direct and/or indirect actions in the recovery of neurogenesis independent of CX3CR1 and NLRP3 profiles in the SGZ, but further study is required to address these hypotheses.
In this study, there were four major limitations and future directions. First, CSDS triggers not only social avoidance behaviors as indicated by this study but also general depressive and anxious states as assessed by forced swimming test (FST) and elevated plus maze test, which are screening tests for depression and anxiety, respectively [43, 73]. In this study, we focused on the behavioral effect of kososan extract on social avoidance as specific depressive- and anxious-like behaviors against aversion induced by CSDS. In another experiment with a slightly different schedule from that of the present study, oral administration of kososan extract for 12 days attenuated a CSDS-triggered increase in immobile behavior, a depressive-like state, in the FST (data not shown). Therefore, future studies on whether kososan extract improves general depressive and anxious states in socially defeated mice are necessary to conclude antidepressant- and anxiolytic-like activities of kososan extract in the CSDS model. Intriguingly, it has also been reported that CSDS enhances hippocampal-dependent fear memory in the contextual fear conditioning paradigm  and that the fear memory is closely linked to microglia-mediated neuroinflammation [75, 76, 77]. Moreover, CSDS-induced social avoidant behavior can be a possible learned fear against conspecific . Given these findings with our results, it is plausible to assume that kososan-induced reduction in hippocampal neuroinflammation may be a possible contributor to alleviation of the hippocampus-dependent fear memory. Studies about kososan’s effect on fear memory would provide additional evidence for a better interpretation of our findings in this study. Second, it has been reported that CSDS causes neuroinflammation throughout the brain, including the prefrontal cortex and amygdala . This finding is likely to support our data in the ex vivo microglial response to LPS reflecting the inflammatory response profiles of microglia in the whole brain [11, 46, 47, 80]. However, further studies on whether kososan extract affects stress-induced neuroinflammation in other brain regions are needed. Third, kososan’s effects in this study would be preventive rather than therapeutic, because drugs were administered concurrent with exposure to CSDS. Further studies investigating the therapeutic effects of kososan extract in comparison with existing antidepressant treatments  using the CSDS paradigm may be useful in the development of therapeutic strategies. Fourth, the active ingredient(s) of kososan extract particularly associated with the anti-inflammatory benefits and behavioral recovery still remains unclear, although there is some evidence indicating that antidepressant-like effects of apigenin  and hesperidin  are involved in their anti-inflammatory activities. It has been reported that nobiletin, a polymethoxyflavone in the peels of citrus fruits such as C. unshiu Markovich (a component herb of kososan), rapidly crosses the blood-brain barrier [81, 82] and that it exerts anti-inflammatory effects in response to LPS-stimulated BV-2 and RAW 264.7 cells (murine microglia and macrophage cell lines, respectively) [83, 84, 85]. Nobiletin has also shown antidepressant-like effects in rodent models [40, 41]. Moreover, our preliminary data from in vitro experiments confirmed some anti-inflammatory effect of nobiletin against LPS-challenged microglia isolated from normal and CSDS-exposed adult mice (unpublished data). The extent to which nobiletin contributed to the benefits of kososan in this study requires further investigation.
This study is the first to report that kososan extract prevents a social avoidant behavior in socially defeated mice. This effect is partially mediated by a reduction in hippocampal neuroinflammation and neurogenesis, presumably by an increased anti-inflammatory, but not decreased pro-inflammatory, phenotype of microglia. Future studies clarifying the mechanisms underlying the anti-neuroinflammatory activity of kososan extract would contribute to the better understanding of the pathology of depression and anxiety and novel therapeutic approaches.
We would like to give special thanks to Dr. Amelia J. Eisch at the University of Texas Southwestern Medical Center at Dallas for teaching us about a technique of the CSDS paradigm. We also thank Ms. Yuri Ando for technical assistance on immunohistochemistry.
This work was supported by JSPS Grants-in-Aid for Scientific Research (C) [grant numbers 26460918 and 17K09320 to NI], the Uehara Memorial Foundation in 2015 (to NI), and Kitasato University Research Grants for Young Researchers in 2011 and 2014 (to NI).
Availability of data and materials
All data are provided in this manuscript and its supplementary information files.
NI designed and conducted most of the experiments, analyzed the data, and drafted the manuscript. EH assisted with the behavioral experiments. TI and AH helped to perform the immunohistochemical analyses. TN, YK, HK, TO, TH, and HO discussed the results and helped to edit the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
All animal experiments were approved by the Institutional Animal Care and Use Committee of Kitasato University and performed in accordance with the Guidelines for the Care and Use of Laboratory Animals of Kitasato University and the National Research Council Guide for the Care and Use of Laboratory Animals in Japan.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 3.Paunio T, Korhonen T, Hublin C, Partinen M, Koskenvuo K, Koskenvuo M, Kaprio J. Poor sleep predicts symptoms of depression and disability retirement due to depression. J Affect Disord. 2014;172C:381–89.Google Scholar
- 8.Krishnan V, Han MH, Mazei-Robison M, Iniguez SD, Ables JL, Vialou V, Berton O, Ghose S, Covington 3rd HE, Wiley MD, et al. AKT signaling within the ventral tegmental area regulates cellular and behavioral responses to stressful stimuli. Biol Psychiatry. 2008;64:691–700.CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Walker AK, Rivera PD, Wang Q, Chuang JC, Tran S, Osborne-Lawrence S, Estill SJ, Starwalt R, Huntington P, Morlock L, et al. The P7C3 class of neuroprotective compounds exerts antidepressant efficacy in mice by increasing hippocampal neurogenesis. Mol Psychiatry. 2015;20:500–8.CrossRefPubMedGoogle Scholar
- 12.Tanaka K, Furuyashiki T, Kitaoka S, Senzai Y, Imoto Y, Segi-Nishida E, Deguchi Y, Breyer RM, Breyer MD, Narumiya S. Prostaglandin E2-mediated attenuation of mesocortical dopaminergic pathway is critical for susceptibility to repeated social defeat stress in mice. J Neurosci. 2012;32:4319–29.CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Couch Y, Anthony DC, Dolgov O, Revischin A, Festoff B, Santos AI, Steinbusch HW, Strekalova T. Microglial activation, increased TNF and SERT expression in the prefrontal cortex define stress-altered behaviour in mice susceptible to anhedonia. Brain Behav Immun. 2013;29:136–46.CrossRefPubMedGoogle Scholar
- 24.Zhao Q, Wu X, Yan S, Xie X, Fan Y, Zhang J, Peng C, You Z. The antidepressant-like effects of pioglitazone in a chronic mild stress mouse model are associated with PPARgamma-mediated alteration of microglial activation phenotypes. J Neuroinflammation. 2016;13:259.CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Hanawa T. Kososan and Hangekobokuto. J Kampo Medicine. 1995;42:418–26.Google Scholar
- 27.Nagai T, Narikawa T, Ito N, Takeda T, Hanawa T, Yamada H. Antidepressant-like effect of a Kampo (Japanese herbal) medicine, kososan, against the interferon-α-induced depressive-like model mice. J Trad Med. 2008;25:74–80.Google Scholar
- 29.Ito N, Hori A, Yabe T, Nagai T, Oikawa T, Yamada H, Hanawa T. Involvement of neuropeptide Y signaling in the antidepressant-like effect and hippocampal cell proliferation induced by kososan, a Kampo medicine, in the stress-induced depression-like model mice. Biol Pharm Bull. 2012;35:1775–83.CrossRefPubMedGoogle Scholar
- 30.Nagai T, Hashimoto R, Okuda SM, Kodera Y, Oh-Ishi M, Maeda T, Ito N, Hanawa T, Kiyohara H, Yamada H. Antidepressive-like effect of a Kampo (traditional Japanese) medicine, kososan (Xiang Su San) in a stress-induced depression-like mouse model: proteomic analysis of hypothalamus. Trad & Kampo Med. 2015;2:50–9.CrossRefGoogle Scholar
- 39.Donato F, Borges Filho C, Giacomeli R, Alvater EE, Del Fabbro L, Antunes Mda S, de Gomes MG, Goes AT, Souza LC, Boeira SP, Jesse CR. Evidence for the involvement of potassium channel inhibition in the antidepressant-like effects of hesperidin in the tail suspension test in mice. J Med Food. 2015;18:818–23.CrossRefPubMedPubMedCentralGoogle Scholar
- 56.Hammels C, Prickaerts J, Kenis G, Vanmierlo T, Fischer M, Steinbusch HW, van Os J, van den Hove DL, Rutten BP. Differential susceptibility to chronic social defeat stress relates to the number of Dnmt3a-immunoreactive neurons in the hippocampal dentate gyrus. Psychoneuroendocrinology. 2015;51:547–56.CrossRefPubMedGoogle Scholar
- 60.Yamashita K, Niwa M, Kataoka Y, Shigematsu K, Himeno A, Tsutsumi K, Nakano-Nakashima M, Sakurai-Yamashita Y, Shibata S, Taniyama K. Microglia with an endothelin ETB receptor aggregate in rat hippocampus CA1 subfields following transient forebrain ischemia. J Neurochem. 1994;63:1042–51.CrossRefPubMedGoogle Scholar
- 75.Fuertig R, Azzinnari D, Bergamini G, Cathomas F, Sigrist H, Seifritz E, Vavassori S, Luippold A, Hengerer B, Ceci A, Pryce CR. Mouse chronic social stress increases blood and brain kynurenine pathway activity and fear behaviour: both effects are reversed by inhibition of indoleamine 2,3-dioxygenase. Brain Behav Immun. 2016;54:59–72.CrossRefPubMedGoogle Scholar
- 82.Saigusa D, Shibuya M, Jinno D, Yamakoshi H, Iwabuchi Y, Yokosuka A, Mimaki Y, Naganuma A, Ohizumi Y, Tomioka Y, Yamakuni T. High-performance liquid chromatography with photodiode array detection for determination of nobiletin content in the brain and serum of mice administrated the natural compound. Anal Bioanal Chem. 2011;400:3635–41.CrossRefPubMedGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.